Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Under provisions of the Affordable Care Act, insurers must cover costs related to PrEP.
Currently, fewer than 1 in 10 women eligible for HIV prevention medications are taking them.
The long-acting regimen will enable some adolescents to take their HIV treatment just six times a year.
After three years, nearly 90% in both groups maintained viral suppression.
The every-other-month schedule of injectable cabotegravir plus rilpivirine enables some people to take HIV treatment just six times a year.
Using the new dosing schedule, injectable cabotegravir and rilpivirine can be administered just six times a year.
COVID-19, HIV vaccine and cure news, and long-acting HIV treatment and prevention topped the news again this year.
Every-other-month cabotegravir injections may work even better than daily pills for HIV prevention.
Starting today, the CDC recommends that clinicians prescribe pre-exposure prophylaxis to anyone who asks for it.
The long-acting injectable regimen suppressed HIV in more than 90% of study participants, including those with obesity.
Long-acting injections given every two months could soon offer a new option for HIV pre-exposure prophylaxis.
Injections of cabotegravir given once every two months may work even better than daily pills for HIV prevention.
According to a recent study, transgender women might benefit more than they think from the prevention pill.
Twice monthly injections for HIV prevention could be approved early next year.
New analyses show that the long-acting injections may be even more effective than previously reported.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.